Twist Bioscience Corporation revenue by segment TWST

Annual Quarterly

Twist Bioscience Corporation splits its revenue into 5 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Jun 30, 2026 was Ngs Tools at $61.8 million, 52% of the total.

USD in millions. The percent under a figure is the change from the same quarter a year earlier.

Line	TTM Jun 30, 2026	Q3 FY2026 Jun 30, 2026	Q2 FY2026 Mar 31, 2026	Q1 FY2026 Dec 31, 2025	Q4 FY2025 Sep 30, 2025	Q3 FY2025 Jun 30, 2025	Q2 FY2025 Mar 31, 2025	Q1 FY2025 Dec 31, 2024	Q4 FY2024 Sep 30, 2024
Revenue	432	118	111	104	99	96	93	89	85
Ngs Tools	—	62 +11.8% share 52.2%	57 +12.3% share 51.9%	53 +8.2% share 50.8%	53 +16.5% share 53.6%	55 share 57.6%	51 share 55.1%	49 share 54.8%	46 share 53.8%
Antibody Discovery	—	57 +38.7% share 47.8%	53 +27.9% share 48.1%	51 +27.4% share 49.2%	6 +21.6% share 6.5%	41 share 42.4%	42 share 44.9%	40 share 45.2%	5 share 6.3%
Synthetic Genes	—	—	—	—	31 +21.7% share 31.5%	28 share 28.8%	—	—	26 share 30.3%
Oligo Pools	—	—	—	—	5 +8.5% share 5.1%	5 share 5.6%	—	—	5 share 5.4%
Dna And Biopharma Libraries	—	—	—	—	3 -8.2% share 3.4%	2 share 2.1%	—	—	4 share 4.3%

How these figures are calculated

Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: TWST (Nasdaq)
Fiscal year ends: September 30
Incorporated in: DE
Headquarters: South San Francisco, CA
SEC filer status: Large accelerated filer
SEC CIK: 1581280

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.